Trelegy Ellipta Indications/Uses

TRELEGY ELLIPTA (fluticasone furoate/umeclidinium/vilanterol) is a combination of an inhaled corticosteroid (ICS), long-acting muscarinic antagonist (LAMA), and a long-acting beta₂-adrenergic agonist (LABA).
COPD: TRELEGY ELLIPTA 100/62.5/25 mcg is indicated in adult patients who are not adequately treated by a combination of an ICS/LABA or a combination of a LAMA/LABA: for the long-term, once daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema; to reduce exacerbations of COPD in patients with a history of exacerbations.
TRELEGY ELLIPTA is not indicated for the relief of acute bronchospasm (see General under Precautions).
Asthma: TRELEGY ELLIPTA 100/62.5/25 mcg and 200/62.5/25 mcg are indicated for the long-term, once-daily, maintenance treatment of asthma in patients aged 18 years and older who are not adequately controlled with a maintenance combination of a medium or high dose of an ICS and a LABA.
TRELEGY ELLIPTA is not indicated for the relief of acute bronchospasm (see General under Precautions).
Pediatrics: Pediatrics (<18 years of age): The safety and efficacy of TRELEGY ELLIPTA in pediatric patients below 18 years of age have not been established.
Geriatrics: Geriatrics (≥ 65 years of age): No dosage adjustment is required in patients 65 years of age and older.